Novo and rival Eli Lilly, which makes the weight loss drug Zepbound, have filed a flurry of lawsuits against medical spas, wellness clinics, and compounding pharmacies for allegedly selling products ...

Focusing on the present, three of the firm’s top selling products are Menveo and ... disease treatment called Nucala and HIV medicine called Cavenuva. GSK plc (NYSE:GSK)’s management provided ...

The HIV specialist – which is majority owned by GlaxoSmithKline – says the ... of more than 50% from its three-drug combination ART products against ViiV’s 22% or so. ViiV is also trying ...

To subscribe, simply enter your email address on our website or click the subscribe button below. Don't worry, we respect your privacy and won't spam your inbox. Your information is safe with us.

Bank of America Securities analyst Graham Parry maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a ...

three of the firm's top selling products are Menveo and Bexsero which are meningitides treatments and Shingris, which is a treatment for herpes. Other fast growing drugs include a lead disease ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

GSK reported $9.1 billion in Q1 revenue, driven by respiratory vaccines and specialty HIV products. It plans to launch 12 new drugs by 2025, including successful new treatments like Arexvy and ...

The turnaround will help to alleviate fears about GSK’s ability to handle the loss of patent protection to key HIV therapy dolutegravir from 2028 onwards, starting in the US. Products containing ...

In a study of more than 3,000 participants, Gilead's twice-yearly lenacapavir delivered a 96% reduction in HIV infections compared with background HIV incidence.